Report Detail
Global (United States, European Union and China) β-blockers Market Research Report 2019-2025
- RnM3579700 |
- 08 July, 2019 |
- Global |
- 111 Pages |
- QYResearch |
- Pharma & Healthcare
β-blockers are a class of medications that are predominantly used to manage abnormal heart rhythms, and to protect the heart from a second heart attack (myocardial infarction) after a first heart attack (secondary prevention). They are also widely used to treat high blood pressure (hypertension), although they are no longer the first choice for initial treatment of most patients.
In 2019, the market size of β-blockers is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for β-blockers.
This report studies the global market size of β-blockers, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the β-blockers sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
Pfizer
Novartis
Merck
Astra Zeneca
Jhonson and Johnson
Eli Lilly
Sanofi
Bristol-Myers Squibb
Bayer
GSK
Teva Pharmaceutical
Market Segment by Product Type
Nonselective Agents
Selective Agents
Market Segment by Application
Abnormal Heart Rhythms
Hypertension
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the β-blockers status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key β-blockers manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of β-blockers are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Major Manufacturers Covered in This Report
- 1.3 Market Segment by Type
- 1.3.1 Global β-blockers Market Size Growth Rate by Type (2019-2025)
- 1.3.2 Nonselective Agents
- 1.3.3 Selective Agents
- 1.4 Market Segment by Application
- 1.4.1 Global β-blockers Market Share by Application (2019-2025)
- 1.4.2 Abnormal Heart Rhythms
- 1.4.3 Hypertension
- 1.5 Study Objectives
- 1.6 Years Considered
2 Global Growth Trends
- 2.1 Global β-blockers Market Size
- 2.1.1 Global β-blockers Revenue 2014-2025
- 2.1.2 Global β-blockers Sales 2014-2025
- 2.2 β-blockers Growth Rate by Regions
- 2.2.1 Global β-blockers Sales by Regions 2014-2019
- 2.2.2 Global β-blockers Revenue by Regions 2014-2019
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
3 Market Share by Manufacturers
- 3.1 β-blockers Sales by Manufacturers
- 3.1.1 β-blockers Sales by Manufacturers 2014-2019
- 3.1.2 β-blockers Sales Market Share by Manufacturers 2014-2019
- 3.2 Revenue by Manufacturers
- 3.2.1 β-blockers Revenue by Manufacturers (2014-2019)
- 3.2.2 β-blockers Revenue Share by Manufacturers (2014-2019)
- 3.2.3 Global β-blockers Market Concentration Ratio (CR5 and HHI)
- 3.3 β-blockers Price by Manufacturers
- 3.4 Key Manufacturers β-blockers Plants/Factories Distribution and Area Served
- 3.5 Date of Key Manufacturers Enter into β-blockers Market
- 3.6 Key Manufacturers β-blockers Product Offered
- 3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
- 4.1 Sales and Revenue for Each Type
- 4.1.1 Nonselective Agents Sales and Revenue (2014-2019)
- 4.1.2 Selective Agents Sales and Revenue (2014-2019)
- 4.2 Global β-blockers Sales Market Share by Type
- 4.3 Global β-blockers Revenue Market Share by Type
- 4.4 β-blockers Price by Type
5 Market Size by Application
- 5.1 Overview
- 5.2 Global β-blockers Sales by Application
6 United States
- 6.1 United States β-blockers Breakdown Data by Company
- 6.2 United States β-blockers Breakdown Data by Type
- 6.3 United States β-blockers Breakdown Data by Application
7 European Union
- 7.1 European Union β-blockers Breakdown Data by Company
- 7.2 European Union β-blockers Breakdown Data by Type
- 7.3 European Union β-blockers Breakdown Data by Application
8 China
- 8.1 China β-blockers Breakdown Data by Company
- 8.2 China β-blockers Breakdown Data by Type
- 8.3 China β-blockers Breakdown Data by Application
9 Rest of World
- 9.1 Rest of World β-blockers Breakdown Data by Company
- 9.2 Rest of World β-blockers Breakdown Data by Type
- 9.3 Rest of World β-blockers Breakdown Data by Application
- 9.4 Rest of World β-blockers Breakdown Data by Countries
- 9.4.1 Rest of World β-blockers Sales by Countries
- 9.4.2 Rest of World β-blockers Revenue by Countries
- 9.4.3 Japan
- 9.4.4 Korea
- 9.4.5 India
- 9.4.6 Southeast Asia
10 Company Profiles
- 10.1 Pfizer
- 10.1.1 Pfizer Company Details
- 10.1.2 Company Description and Business Overview
- 10.1.3 Sales, Revenue and Market Share of β-blockers
- 10.1.4 β-blockers Product Introduction
- 10.1.5 Pfizer Recent Development
- 10.2 Novartis
- 10.2.1 Novartis Company Details
- 10.2.2 Company Description and Business Overview
- 10.2.3 Sales, Revenue and Market Share of β-blockers
- 10.2.4 β-blockers Product Introduction
- 10.2.5 Novartis Recent Development
- 10.3 Merck
- 10.3.1 Merck Company Details
- 10.3.2 Company Description and Business Overview
- 10.3.3 Sales, Revenue and Market Share of β-blockers
- 10.3.4 β-blockers Product Introduction
- 10.3.5 Merck Recent Development
- 10.4 Astra Zeneca
- 10.4.1 Astra Zeneca Company Details
- 10.4.2 Company Description and Business Overview
- 10.4.3 Sales, Revenue and Market Share of β-blockers
- 10.4.4 β-blockers Product Introduction
- 10.4.5 Astra Zeneca Recent Development
- 10.5 Jhonson and Johnson
- 10.5.1 Jhonson and Johnson Company Details
- 10.5.2 Company Description and Business Overview
- 10.5.3 Sales, Revenue and Market Share of β-blockers
- 10.5.4 β-blockers Product Introduction
- 10.5.5 Jhonson and Johnson Recent Development
- 10.6 Eli Lilly
- 10.6.1 Eli Lilly Company Details
- 10.6.2 Company Description and Business Overview
- 10.6.3 Sales, Revenue and Market Share of β-blockers
- 10.6.4 β-blockers Product Introduction
- 10.6.5 Eli Lilly Recent Development
- 10.7 Sanofi
- 10.7.1 Sanofi Company Details
- 10.7.2 Company Description and Business Overview
- 10.7.3 Sales, Revenue and Market Share of β-blockers
- 10.7.4 β-blockers Product Introduction
- 10.7.5 Sanofi Recent Development
- 10.8 Bristol-Myers Squibb
- 10.8.1 Bristol-Myers Squibb Company Details
- 10.8.2 Company Description and Business Overview
- 10.8.3 Sales, Revenue and Market Share of β-blockers
- 10.8.4 β-blockers Product Introduction
- 10.8.5 Bristol-Myers Squibb Recent Development
- 10.9 Bayer
- 10.9.1 Bayer Company Details
- 10.9.2 Company Description and Business Overview
- 10.9.3 Sales, Revenue and Market Share of β-blockers
- 10.9.4 β-blockers Product Introduction
- 10.9.5 Bayer Recent Development
- 10.10 GSK
- 10.10.1 GSK Company Details
- 10.10.2 Company Description and Business Overview
- 10.10.3 Sales, Revenue and Market Share of β-blockers
- 10.10.4 β-blockers Product Introduction
- 10.10.5 GSK Recent Development
- 10.11 Teva Pharmaceutical
11 Value Chain and Sales Channels Analysis
- 11.1 Value Chain Analysis
- 11.2 Sales Channels Analysis
- 11.2.1 β-blockers Sales Channels
- 11.2.2 β-blockers Distributors
- 11.3 β-blockers Customers
12 Market Forecast
- 12.1 Global β-blockers Sales and Revenue Forecast 2019-2025
- 12.2 Global β-blockers Sales Forecast by Type
- 12.3 Global β-blockers Sales Forecast by Application
- 12.4 β-blockers Forecast by Regions
- 12.4.1 Global β-blockers Sales Forecast by Regions 2019-2025
- 12.4.2 Global β-blockers Revenue Forecast by Regions 2019-2025
- 12.5 United States Market Forecast
- 12.6 European Union Market Forecast
- 12.7 China Market Forecast
- 12.8 Rest of World
- 12.8.1 Japan
- 12.8.2 Korea
- 12.8.3 India
13 Research Findings and Conclusion
14 Appendix
- 14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
- 14.1.1.1 Research Programs/Design
- 14.1.1.2 Market Size Estimation
- 14.1.1.3 Market Breakdown and Data Triangulation
- 14.1.2 Data Source
- 14.1.2.1 Secondary Sources
- 14.1.2.2 Primary Sources
- 14.1.1 Methodology/Research Approach
- 14.2 Author Details
Summary:
Get latest Market Research Reports on β-blockers. Industry analysis & Market Report on β-blockers is a syndicated market report, published as Global (United States, European Union and China) β-blockers Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of β-blockers market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
